To include your compound in the COVID-19 Resource Center, submit it here.

Teva's Austedo meets in Phase III tardive dyskinesia study

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said Austedo deutetrabenazine ( SD-809) met the primary endpoint in the Phase

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE